ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 030

The Efficacy and Safety of Intraarticular Injection of Triamcinolone Acetonide versus Triamcinolone Hexacetonide in the Treatment of Juvenile Idiopathic Arthritis

Shiri Rubin 1, Rotem Tal 2, Ori Goldberg 3, Yoel Levinsky 4, Zohar Habot-Wilner 5, Orly Ohana 6, Yulia Gendler 7, Liora Harel 8 and Gil Amarilyo9, 1Schneider Children's hospital of Israel, Tel Aviv university, Petach Tikva, Israel, 2schneider medical center, Ramat Gan, Israel, 3Schneider Children's Medical Center of Israel, Tel Aviv University, Petach Tikva, Israel, 4Schneider Children's Medical Cnetr of Israel, Tel Aviv University, Petach Tikva, Israel, 5Tel Aviv Sourasky Medical Center, Tel Aviv Univrsity, Tel Aviv, Israel, 6Schneider Children's Medical Cener of Israel, Petach Tikva, Israel, 7Schneider Children's Medical Center of Israel, Tel Aviv Univesity, Petach Tikva, Israel, 8Schneider Hospital, Tel Aviv University, Petah-Tiqva, Israel, 9Schneider Hospital, Tel Aviv University, Kibbutz Magal, Israel

Meeting: 2020 Pediatric Rheumatology Symposium

Keywords:

Session Information

The 2020 Pediatric Rheumatology Symposium, originally scheduled for April 29 – May 2, was postponed due to COVID-19; therefore, abstracts were not presented as scheduled.

Date: Friday, May 1, 2020

Title: Poster Breakout 4 – Updates on Therapeutics

Session Type: Poster Breakout Session

Session Time: 4:30PM-5:00PM

Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease of childhood. Intra-articular corticosteroids joint injection (IAJI) with Triamcinolone hexacetonide (TH) or triamcinolone acetonide (TA) is considered as the first-line therapy for oligoarticular JIA. Our unit has experience in treatment with both regimens and therefore we aimed to compare the efficacy and safety of TA versus TH for oligo and poly-articular JIA patient.

Methods: Chart review of JIA patients who were randomly (based on drug availability) treated with TA or TH IAJI between 2010-2019 was conducted. The primary outcomes for efficacy and safety were defined as full recovery of arthritis and occurrence of adverse events (AEs) one month after IAJI respectively.

Results: Overall 239 joints of 80 JIA patients were treated (136 TA/103 TH joints). Complete recovery was documented in 69.1% TA and 71.8% TH groups. 8.8% vs. 11.7% of treated patients with TH and TA respectively had no response or worsening of arthritis (p=0.485). No AEs were documented except of minor scar at 2 joints injection sites.

Conclusion: We demonstrated complete recovery of arthritis in about 70% of IAJI treated patients and similar efficacy of TA and TH regimens along with high safety profile. These findings are specifically important due to limited availability of TH.

Figure 1:Kaplan_Meyer analysis of arthritis relapse rate in 12 month period

Disclosure: S. Rubin, None; R. Tal, None; O. Goldberg, None; Y. Levinsky, None; Z. Habot-Wilner, None; O. Ohana, None; Y. Gendler, None; L. Harel, None; G. Amarilyo, None.

To cite this abstract in AMA style:

Rubin S, Tal R, Goldberg O, Levinsky Y, Habot-Wilner Z, Ohana O, Gendler Y, Harel L, Amarilyo G. The Efficacy and Safety of Intraarticular Injection of Triamcinolone Acetonide versus Triamcinolone Hexacetonide in the Treatment of Juvenile Idiopathic Arthritis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 4). https://acrabstracts.org/abstract/the-efficacy-and-safety-of-intraarticular-injection-of-triamcinolone-acetonide-versus-triamcinolone-hexacetonide-in-the-treatment-of-juvenile-idiopathic-arthritis/. Accessed .

« Back to 2020 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-efficacy-and-safety-of-intraarticular-injection-of-triamcinolone-acetonide-versus-triamcinolone-hexacetonide-in-the-treatment-of-juvenile-idiopathic-arthritis/